Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.

Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, Nishiyama S, Takahashi T, Misu T, Kuroda H, Tanaka S, Nomura K, Hashimoto Y, Callegaro D, Steinman L, Fujihara K, Aoki M.

J Neurol Neurosurg Psychiatry. 2018 Jun 6. pii: jnnp-2018-317969. doi: 10.1136/jnnp-2018-317969. [Epub ahead of print]

2.

A Case of Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder.

Asato Y, Kamitani T, Ootsuka K, Kuramochi M, Nakanishi K, Shimada T, Takahashi T, Misu T, Aoki M, Fujihara K, Kawabata Y.

Intern Med. 2018 May 18. doi: 10.2169/internalmedicine.0580-17. [Epub ahead of print]

3.

Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study.

Nishiyama S, Misu T, Shishido-Hara Y, Nakamichi K, Saijo M, Takai Y, Takei K, Yamamoto N, Kuroda H, Saito R, Watanabe M, Tominaga T, Nakashima I, Fujihara K, Aoki M.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 10;5(1):e415. doi: 10.1212/NXI.0000000000000415. eCollection 2018 Jan.

4.

Driver Behavior and Performance with Augmented Reality Pedestrian Collision Warning: An Outdoor User Study.

Kim H, Gabbard JL, Anon AM, Misu T.

IEEE Trans Vis Comput Graph. 2018 Apr;24(4):1515-1524. doi: 10.1109/TVCG.2018.2793680.

PMID:
29543169
5.

An Evaluation of "Drug Ineffective" Postmarketing Reports in Drug Safety Surveillance.

Misu T, Kortepeter CM, Muñoz MA, Wu E, Dal Pan GJ.

Drugs Real World Outcomes. 2018 Jun;5(2):91-99. doi: 10.1007/s40801-018-0131-3.

6.

Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency.

Ishiguro C, Misu T, Iwasa E, Izawa T.

Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1314-1320. doi: 10.1002/pds.4252. Epub 2017 Jul 19.

PMID:
28722235
7.

Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies.

Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, Nishiyama S, Watanabe M, Tanji H, Kobayashi M, Misu T, Aoki M, Fujihara K.

J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):534-536. doi: 10.1136/jnnp-2016-315094. Epub 2017 Feb 16. No abstract available.

PMID:
28209651
8.

MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.

Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K.

Neurol Neuroimmunol Neuroinflamm. 2017 Jan 16;4(2):e322. doi: 10.1212/NXI.0000000000000322. eCollection 2017 Mar.

9.

Hypoxia-like tissue injury and glial response contribute to Balo concentric lesion development.

Takai Y, Misu T, Nishiyama S, Ono H, Kuroda H, Nakashima I, Saito R, Kanamori M, Sonoda Y, Kumabe T, Mugikura S, Watanabe M, Aoki M, Fujihara K.

Neurology. 2016 Nov 8;87(19):2000-2005. Epub 2016 Oct 12.

10.

Impact of the Great East Japan Earthquake in 2011 on MS and NMOSD: a study in Sendai, Japan.

Kanamori Y, Nakashima I, Takai Y, Misu T, Kuroda H, Nishiyama S, Takahashi T, Sato S, Fujimori J, Higuchi J, Itoyama Y, Aoki M, Fujihara K.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):362-364. doi: 10.1136/jnnp-2016-313890. Epub 2016 Aug 17. No abstract available.

PMID:
27535942
11.

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD.

Zeka B, Hastermann M, Kaufmann N, Schanda K, Pende M, Misu T, Rommer P, Fujihara K, Nakashima I, Dahle C, Leutmezer F, Reindl M, Lassmann H, Bradl M.

Acta Neuropathol Commun. 2016 Aug 8;4(1):82. doi: 10.1186/s40478-016-0355-y.

12.

Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: Pathogenetic implications in neuromyelitis optica.

Nishiyama S, Misu T, Nuriya M, Takano R, Takahashi T, Nakashima I, Yasui M, Itoyama Y, Aoki M, Fujihara K.

Biochem Biophys Rep. 2016 May 18;7:45-51. doi: 10.1016/j.bbrep.2016.05.012. eCollection 2016 Sep.

13.

Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica.

Akaishi T, Nakashima I, Takeshita T, Mugikura S, Sato DK, Takahashi T, Nishiyama S, Kurosawa K, Misu T, Nakazawa T, Aoki M, Fujihara K.

J Neuroimmunol. 2016 Apr 15;293:28-33. doi: 10.1016/j.jneuroim.2016.02.004. Epub 2016 Feb 10.

PMID:
27049558
14.

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.

Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Hyun JW, Oliveira LM, Reindl M, Seifert-Held T, Sepulveda M, Siritho S, Waters PJ, Kurosawa K, Akaishi T, Kuroda H, Misu T, Prayoonwiwat N, Berger T, Saiz A, Kim HJ, Nomura K, Callegaro D, Fujihara K, Aoki M.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1257-1259. doi: 10.1136/jnnp-2015-312676. Epub 2016 Jan 22. No abstract available.

PMID:
26800711
15.

Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody.

Kurosawa K, Misu T, Takai Y, Sato DK, Takahashi T, Abe Y, Iwanari H, Ogawa R, Nakashima I, Fujihara K, Hamakubo T, Yasui M, Aoki M.

Acta Neuropathol Commun. 2015 Dec 4;3:82. doi: 10.1186/s40478-015-0259-2.

16.

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.

Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J, Takai Y, George J, Kitley J, Santos ME, Nour JM, Cheng F, Kuroda H, Misu T, Martins-da-Silva A, DeLuca GC, Vincent A, Palace J, Waters P, Fujihara K, Leite MI.

Neurology. 2016 Jan 5;86(1):79-87. doi: 10.1212/WNL.0000000000002208. Epub 2015 Nov 18.

17.

Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS.

Zeka B, Hastermann M, Hochmeister S, Kögl N, Kaufmann N, Schanda K, Mader S, Misu T, Rommer P, Fujihara K, Illes Z, Leutmezer F, Sato DK, Nakashima I, Reindl M, Lassmann H, Bradl M.

Acta Neuropathol. 2015 Dec;130(6):783-98. doi: 10.1007/s00401-015-1501-5. Epub 2015 Nov 3.

18.

[MRI and CSF features in neuromyelitis optica].

Misu T.

Nihon Rinsho. 2015 Sep;73 Suppl 7:277-82. Japanese. No abstract available.

PMID:
26480713
19.

High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG.

Miyazaki-Komine K, Takai Y, Huang P, Kusano-Arai O, Iwanari H, Misu T, Koda K, Mitomo K, Sakihama T, Toyama Y, Fujihara K, Hamakubo T, Yasui M, Abe Y.

Br J Pharmacol. 2016 Jan;173(1):103-14. doi: 10.1111/bph.13340. Epub 2015 Nov 4.

20.

[Clinical characteristics of four patients with temporal lobe epilepsy associated with elevated anti-GAD antibodies].

Akaishi T, Jin K, Kato K, Itabashi H, Misu T, Tateyama M, Iwasaki M, Aoki M, Nakasato N.

Rinsho Shinkeigaku. 2015;55(11):804-9. doi: 10.5692/clinicalneurol.cn-000740. Epub 2015 Sep 11. Japanese.

PMID:
26369378
21.

Leukoencephalopathy resolution after atypical mycobacterial treatment: a case report.

Oliveira MC, Sato DK, Soares-Neto HR, Lucato LT, Callegaro D, Nitrini R, Medeiros RS, Misu T, Fujihara K, Castro LH.

BMC Neurol. 2015 Sep 2;15:159. doi: 10.1186/s12883-015-0415-0.

22.

Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica.

Akaishi T, Nakashima I, Misu T, Fujihara K, Aoki M.

J Neuroimmunol. 2015 Jun 15;283:70-3. doi: 10.1016/j.jneuroim.2015.05.007. Epub 2015 May 9.

PMID:
26004160
23.

Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder.

Shimizu Y, Fujihara K, Ohashi T, Nakashima I, Yokoyama K, Ikeguch R, Takahashi T, Misu T, Shimizu S, Aoki M, Kitagawa K.

Mult Scler. 2016 Oct;22(11):1413-1420. Epub 2015 Apr 28.

PMID:
25921053
24.

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

Waters P, Woodhall M, O'Connor KC, Reindl M, Lang B, Sato DK, Juryńczyk M, Tackley G, Rocha J, Takahashi T, Misu T, Nakashima I, Palace J, Fujihara K, Leite MI, Vincent A.

Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e89. doi: 10.1212/NXI.0000000000000089. eCollection 2015 Jun.

25.

MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study.

Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, Kurosawa K, Kaneko K, Kuroda H, Nishiyama S, Misu T, Nakazawa T, Fujihara K, Aoki M.

J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):446-8. doi: 10.1136/jnnp-2014-310206. Epub 2015 Mar 6. No abstract available.

PMID:
25749692
26.

Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies.

Hino-Fukuyo N, Haginoya K, Nakashima I, Sato DK, Takahashi T, Misu T, Fujihara K, Hirose M, Kakisaka Y, Uematsu M, Kobayashi T, Kure S.

Brain Dev. 2015 Oct;37(9):849-52. doi: 10.1016/j.braindev.2015.02.006. Epub 2015 Mar 3.

PMID:
25748628
27.

Multiple sclerosis in Japan appears to be a milder disease compared to the UK.

Piccolo L, Kumar G, Nakashima I, Misu T, Kong Y, Wakerley B, Ryan S, Cavey A, Fujihara K, Palace J.

J Neurol. 2015;262(4):831-6. doi: 10.1007/s00415-015-7637-3. Epub 2015 Jan 22.

PMID:
25605435
28.

Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation.

Tateyama M, Fujihara K, Misu T, Arai A, Kaneta T, Aoki M.

BMJ Open. 2015 Jan 12;5(1):e006763. doi: 10.1136/bmjopen-2014-006763.

29.

The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model.

Geis C, Ritter C, Ruschil C, Weishaupt A, Grünewald B, Stoll G, Holmoy T, Misu T, Fujihara K, Hemmer B, Stadelmann C, Bennett JL, Sommer C, Toyka KV.

Exp Neurol. 2015 Mar;265:8-21. doi: 10.1016/j.expneurol.2014.12.015. Epub 2014 Dec 24.

30.

[In vivo experimental models of neuromyelitis optica].

Misu T.

Nihon Rinsho. 2014 Nov;72(11):1941-8. Japanese.

PMID:
25518375
31.

AQP4 in biopsied demyelinating lesions as a diagnostic clue to NMOSD and MS: final answer?

Fujihara K, Misu T.

Neurology. 2015 Jan 13;84(2):110-1. doi: 10.1212/WNL.0000000000001135. Epub 2014 Dec 10. No abstract available.

PMID:
25503619
32.

Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.

Ikeda K, Kiyota N, Kuroda H, Sato DK, Nishiyama S, Takahashi T, Misu T, Nakashima I, Fujihara K, Aoki M.

Mult Scler. 2015 Apr;21(5):656-9. doi: 10.1177/1352458514551455. Epub 2014 Sep 25.

PMID:
25257613
33.

MOG-IgG serological status matters in paediatric ADEM.

Misu T, Sato DK, Nakashima I, Fujihara K.

J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):242. doi: 10.1136/jnnp-2014-308723. Epub 2014 Aug 18. No abstract available.

PMID:
25136054
34.

Audiological evidence of therapeutic effect of steroid treatment in neuromyelitis optica with hearing loss.

Takanashi Y, Misu T, Oda K, Miyazaki H, Yahata I, Hidaka H, Fujihara K, Kawase T, Kobayashi T, Katori Y.

J Clin Neurosci. 2014 Dec;21(12):2249-51. doi: 10.1016/j.jocn.2014.04.019. Epub 2014 Jul 29.

PMID:
25085730
35.

Pain in neuromyelitis optica--prevalence, pathogenesis and therapy.

Bradl M, Kanamori Y, Nakashima I, Misu T, Fujihara K, Lassmann H, Sandkühler J.

Nat Rev Neurol. 2014 Sep;10(9):529-36. doi: 10.1038/nrneurol.2014.129. Epub 2014 Jul 29. Review.

PMID:
25072195
36.

Anti-N-methyl-D-aspartate receptor encephalitis with multiphasic demyelination.

Kaneko K, Sato DK, Misu T, Kurosawa K, Nakashima I, Fujihara K, Aoki M.

Ann Neurol. 2014 Sep;76(3):462-4. doi: 10.1002/ana.24224. Epub 2014 Jul 26. No abstract available.

PMID:
25044002
37.

A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion.

Sawada J, Orimoto R, Misu T, Katayama T, Aizawa H, Asanome A, Takahashi K, Saito T, Anei R, Kamada K, Miyokawa N, Takahashi T, Fujihara K, Hasebe N.

Mult Scler. 2014 Sep;20(10):1413-6. doi: 10.1177/1352458514540834. Epub 2014 Jul 1.

PMID:
24986696
38.

Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.

Sato DK, Callegaro D, de Haidar Jorge FM, Nakashima I, Nishiyama S, Takahashi T, Simm RF, Apostolos-Pereira SL, Misu T, Steinman L, Aoki M, Fujihara K.

Ann Neurol. 2014 Aug;76(2):305-9. doi: 10.1002/ana.24208. Epub 2014 Jul 9.

39.

An autopsy case involving a 12-year history of amyotrophic lateral sclerosis with CIDP-like polyneuropathy.

Akaishi T, Tateyama M, Kato K, Miura E, Izumi R, Endo K, Sugeno N, Suzuki N, Baba T, Misu T, Kikuchi A, Hasegawa T, Konosu-Fukaya S, Fujishima F, Suzuki H, Nakashima I, Aoki M.

Intern Med. 2014;53(12):1371-5. Epub 2014 Jun 15.

40.

Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.

Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, Kuroda H, Fujihara K, Aoki M.

J Neuroimmunol. 2014 Mar 15;268(1-2):95-8. doi: 10.1016/j.jneuroim.2014.01.008. Epub 2014 Jan 23.

PMID:
24507619
41.

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.

Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Lino AM, Misu T, Leite MI, Aoki M, Fujihara K.

Neurology. 2014 Feb 11;82(6):474-81. doi: 10.1212/WNL.0000000000000101. Epub 2014 Jan 10.

42.

T cell-activation in neuromyelitis optica lesions plays a role in their formation.

Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer MT, Machado-Santos J, Mader S, Ellwart JW, Misu T, Fujihara K, Wekerle H, Reindl M, Lassmann H, Bradl M.

Acta Neuropathol Commun. 2013 Dec 24;1:85. doi: 10.1186/2051-5960-1-85.

43.

The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T.

Brain Pathol. 2014 Jan;24(1):83-97. doi: 10.1111/bpa.12099. Review.

44.

Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats.

Kitic M, Hochmeister S, Wimmer I, Bauer J, Misu T, Mader S, Reindl M, Fujihara K, Lassmann H, Bradl M.

Acta Neuropathol Commun. 2013 May 8;1:5. doi: 10.1186/2051-5960-1-5.

45.

Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: diagnostic considerations.

Sato DK, Misu T, Rocha CF, Callegaro D, Nakashima I, Aoki M, Fujihara K, Lana-Peixoto MA.

Mult Scler. 2014 Apr;20(5):621-6. doi: 10.1177/1352458513505350. Epub 2013 Sep 12.

46.

A novel monoclonal antibody against the C-terminal region of aquaporin-4.

Ramadhanti J, Huang P, Kusano-Arai O, Iwanari H, Sakihama T, Misu T, Fujihara K, Hamakubo T, Yasui M, Abe Y.

Monoclon Antib Immunodiagn Immunother. 2013 Aug;32(4):270-6. doi: 10.1089/mab.2013.0007.

47.

[Pathogenesis of neuromyelitis optica].

Misu T, Fujihara K.

Nihon Rinsho. 2013 May;71(5):823-8. Review. Japanese.

PMID:
23777089
48.

Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.

Sato DK, Nakashima I, Takahashi T, Misu T, Waters P, Kuroda H, Nishiyama S, Suzuki C, Takai Y, Fujihara K, Itoyama Y, Aoki M.

Neurology. 2013 Jun 11;80(24):2210-6. doi: 10.1212/WNL.0b013e318296ea08. Epub 2013 May 15.

PMID:
23677744
49.

Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica.

Misu T, Höftberger R, Fujihara K, Wimmer I, Takai Y, Nishiyama S, Nakashima I, Konno H, Bradl M, Garzuly F, Itoyama Y, Aoki M, Lassmann H.

Acta Neuropathol. 2013 Jun;125(6):815-27. doi: 10.1007/s00401-013-1116-7. Epub 2013 Apr 12.

50.

[NMO spectrum disorders and anti AQP4 antibody].

Takai Y, Misu T, Takahashi T, Nakashima I, Fujihara K.

Brain Nerve. 2013 Apr;65(4):333-43. Review. Japanese.

PMID:
23568981

Supplemental Content

Support Center